Seret, G., Hanrotel, C., Bendaoud, B., Le Meur, Y., & Renaudineau, Y. (2013). Homozygous FCGR3A-158F mutation is associated with delayed B-cell depletion following rituximab but with preserved efficacy in a patient with refractory lupus nephritis. Clin Kidney J.
シカゴスタイル引用形Seret, Guillaume, Catherine Hanrotel, Boutahar Bendaoud, Yannick Le Meur, , Yves Renaudineau. "Homozygous FCGR3A-158F Mutation Is Associated With Delayed B-cell Depletion Following Rituximab but With Preserved Efficacy in a Patient With Refractory Lupus Nephritis." Clin Kidney J 2013.
MLA引用形式Seret, Guillaume, et al. "Homozygous FCGR3A-158F Mutation Is Associated With Delayed B-cell Depletion Following Rituximab but With Preserved Efficacy in a Patient With Refractory Lupus Nephritis." Clin Kidney J 2013.